Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: Effect on survival

Journal of the National Cancer Institute

Volumn 91, Issue 1, 1999, Pages 73-79

  Orlow, Irene ^c   Drobnjak, Marija ^c   Zhang, Zuo Feng ^b   Lewis, Jonathan ^a   Woodruff, James M ^c   Brennan, Murray F ^a   Cordon Cardo, Carlos ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE DELETION; HUMAN; HUMAN TISSUE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE;

EID: 0033528084     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.1.73     Document Type: Article

References (51)

1. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-7.
2. Clurman BE, Roberts JM. Cell cycle and cancer [editorial]. J Natl Cancer Inst 1995;87: 1499-501.
3. Cordon-Cardo C. Mutation of cell cycle regulators. Am J Pathol 1995;147:545-59.
4. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
5. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
6. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
7. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22.
8. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
9. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, et al. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995;55:1211-4.
10. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-49.
11. CIP1 Cdk inhibitory family, is a candidate tumor suppressor gene. Genes Dev 1995;9:650-62.
12. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
13. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264: 436-40.
14. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994;371:257-61.
15. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994;8: 2939-52.
16. Okuda T, Hirai H, Valentine VA, Shurtleff SA, Kidd VJ, Lahti JM, et al. Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d, an inhibitor of cyclin D-dependent kinases. Genomics 1995;29:623-30.
17. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
18. Duro D, Bernard O, Della Valle V, Berger R, Larsen CJ. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 1995;11:21-9.
19. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, et al. A novel p16INK4A transcript. Cancer Res 1995;55:2995-7.
20. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, et al. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 1995;55:2988-94.
21. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
22. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
23. Orndal C, Carlen B, Akerman M, Willen H, Mandahl N, Heim S, et al. Chromosomal abnormality t(9;22) (q22;q12) in an extraskeletal myxoid chondrosarcoma characterized by fine needle aspiration cytology, electron mycroscopy, immunohistochemistry and DNA flow cytometry. Cytopathology 1991;2:261-70.
24. Sreekantaiah C, Ladanyi M, Rodriguez E, Chaganti RS. Chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classification, and molecular mechanisms. Am J Pathol 1994;144:1121-34.
25. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994;54:6353-8.
26. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995;87:1524-9.
27. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, et al. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 1995;55:514-7.
28. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 1996;86:136-42.
29. Takeuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JW, et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15/ MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995;86:755-60.
30. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, et al. Methylation of the 5′ CpG island of the p16/ CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55:4531-5.
31. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/ MTS1 in human cancers. Nat Med 1995;1: 686-92.
32. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
33. ARF. Cell 1997;91:649-59.
34. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54: 794-9.
35. Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84:1251-6.
36. Metha CR, Patel NR. A network algorithm for performing Fisher's Exact test rxc contingency tables. J Am Statist Assoc 1983;78:427-34.
37. SAS/STAT user guide, version 6. Cary (NC): SAS Institute Inc.; 1990.
38. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
39. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
40. Cox DR. Regression models and life table. J R Statist Soc 1972;34:187-220.
41. Cox DR. Partial likelihood. Biometrika 1975; 62:269-79.
42. Van Dyke TA. Analysis of viral-host protein interactions and tumorigenesis in transgenic mice. Semin Cancer Biol 1994;5:47-60.
43. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 1994;7:480-4.
44. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997;57:1217-21.
45. Ink4. Cancer Res 1994;54:5816-20.
46. Dosaka-Akita H, Hu SX, Fujino M, Harada M, Kinoshita I, Xu HJ, et al. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status in prognosis. Cancer 1997;79:1329-37.
47. Cote RJ, Dunn MD, Chaterjee SJ, Stein JP, Shi SR, Tran QC, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090-4.
48. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-84.
49. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996;85:721-32.
50. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumori-genesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-44.
51. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-20.